Patent · US Expired

Tumor necrosis factor antagonists and their use in endometriosis

US6663865B1 · kind B1 · utility

8Cited by

1References

6Claims

0Family size

Assignee

APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

Inventors

Francesco Borrelli · Kensington, US
Mauro D'Antonio · Caserta, IT
Fabrizio Martelli · Roma, IT

Key dates

Filing date	Sep 14, 2001
Grant date	Dec 16, 2003
Priority date	—
Expiry date	Sep 14, 2021

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected from among several classes but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.